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Morphine                                                                                  Methadone                                                                           Fentanyl 
Opioid rotation of Morphine and Methadone: Adverse effects   
Morphine                                                     Methadone 
        Consitpation            Fewer instances of constipation 
        Nausea / Vomiting           Decreased Nausea / Vomiting 
        Sedation / Drowsiness           Increase in Alertness 
 
* In one study, switching from oral to subcutaneous  morphine produced less 
drowsiness and nausea / vomiting.   
CONCLUSON: Methadone can be a superior analgesic for some palliative cancer 
patients, but Morphine continues to be the first line opioid recommended due to its 
effectiveness.  Methadone and Fentanyl have shown to be quite comparable in 
effectiveness, and physicians are increasing the use of these two opioids.  However, it 
is suggested that Methadone be studied further as a first line opioid for cancer pain.  
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METHADONE CARDIAC TOXICITY: 
• In studies, it was not confirmed that oral 
Methadone can cause cardiac toxicity. 
• There is a direct correlation between IV 
Methadone and QT wave prolongation.  
• It is suggested to routinely perform 
electrocardiograms prior to initiating the 
infusion, 24 to 72 hours later, and again 24 
to 72 hours after each increase in the dose. 
• Monitor electrolytes, especially potassium.  
 Use is increasing among 
physicians, but not all respond well 
to this drug. 
 Decreased adverse effects 
comparred to morphine –reduces 
polypharmacy. 
 Good choice as second line opioid 
when loss of responsiveness to 
another opioid.  
Fentanyl and Methadone are 
comparable in the effectiveness of pain 
management and the amount of 
adverse effects.  
 Shown to be first line analgesic for cancer 
pain.  
 Best choice for opioid naive. 
 Hepatic metabolism and renal elimination. 
 Price ranges according to international price 
of poppy  (can make it unaffordable in 
developing countries) 
 Naturally derived from the poppy. 
 Wide availability. 
 Varied formulations of dosing.  
 High incidence of adverse effects such as 
constipation, nausea, myoclonus and 
sedation which results in polypharmacy.  
 Synthetic and easily manufactured.  
 Affordable/ low cost  
 Excellent bioavailability 
 Low renal elimination and metabolized in the liver– great for renal failure patients.  
 Decreased adverse effects compared to morphine– reduces polypharmacy. 
 Potent N-methyl-D-aspartate receptor antagonist which makes it quite effective 
for neuropathic pain.  
 Good choice as second line opioid when loss of responsiveness to another 
opioid.  
 In studies, it had not produced superior analgesia compared to other opioids.  
 Long and unpredictable half life, making it difficult for titration, and so needing 
cautious dosing and monitoring by physicians.  
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Methadone Use in Palliative Care Patients  
 
Methadone is increasingly being used for palliative cancer patients for 
pain management.  Physicians are “rotating” opioids to help reduce 
opioid side effects, and help increase pain response due to tolerance 
of another opioid.  Methadone has been compared to other opioids in 
studies in which it has been rotated with another opioid. The studies 
compared the adverse effects, cost, and the rate of success to 
achieve adequate pain management.  
METHADONE IV 
ADMINISTRATION: 
• Sedative effects will increase with 
IV Methadone infusion over the 
first 12 hours after initiation and 
increasing the infusion.  
• The infusion should not be 
increased during the initial 12 
hours.  
• Give PRN doses for breakthrough 
pain.  
 
METHADONE NURSING CONSIDERATIONS: 
• The general rule for Methadone is, “Start Low, Go Slow.” 
• Dosing increases should not be made more frequently than every 
5-7 days.  
• Monitor for excessive drowsiness, unsteadiness, or confusion during 
the first 3 to 5 days, and notify the physician if effects persist or 
worsen beyond this time.  
• Watch for drug tolerance in those with a history of drug abuse, as 
methadone can cause physical and psychological dependence. 
• Monitor patients with head injuries or other conditions that may 
increase intracranial pressure (brain tumors) because methadone may 
further increase intracranial pressure.  
• Monitor patients for cardiac arrhythmias , hypotension, and vasovagal 
syncope because methadone may cause cholinergic effects in 
patients with cardiac disease, resulting in bradycardia and peripheral 
vasodilation.  
 
